Pfizer Launches AI Certification Program for Global Workforce

Pfizer has implemented a new certification program designed for all employee roles worldwide, aiming to enhance AI proficiency. The initiative, led by CEO Albert Bourla, seeks to accelerate drug discovery and manufacturing processes while emphasizing the preservation of the human element. Within four months of the program's announcement, 98 percent of eligible employees completed the first course.

The AI competency program launched by Pfizer for its global workforce aims to integrate artificial intelligence into every area of the company, from laboratory research to manufacturing and supply chain operations. CEO Albert Bourla aims to accelerate drug discovery and development processes with this initiative.

One of the key features of the program is the emphasis on preserving the human element in all AI applications, including clinical trials, drug development, and research activities. In the four-month period following the launch of the first course, 98 percent of eligible Pfizer employees successfully completed the training.